BioVector? TB096 (TB096-2) 人源 IDH1 突變型星形細胞瘤細胞系

BioVector? TB096 (TB096-2) Human IDH1-Mutated Astrocytoma Cell Line Manual

第一部分 中文說明

一 產(chǎn)品基本信息與遺傳學背景

• 細胞名稱：TB096（常寫作 TB096-2 或 TB096-0096）人源 IDH1 突變型星形細胞瘤細胞系

• 物種來源：人源（Human），衍生自一名 26 歲男性間變性星形細胞瘤（Anaplastic Astrocytoma, WHO Grade III）患者。由杜克大學（Duke University）腦腫瘤生物樣本庫通過患者知情同意建立。

• 核心遺傳學與分子標志：

  • IDH1 R132H 雜合突變（經(jīng)典腫瘤標志）：本細胞系基因組在 IDH1（NADP+ 依賴性異檸檬酸脫氫酶 1）編碼區(qū)的 Arg132 (R132) 位置存在特異性單點突變（常見為雜合子，即一個等位基因為野生型，另一個基因為突變型，變?yōu)榻M氨酸 His/H）。

  • 致癌代謝產(chǎn)物 D-2HG 高分泌（Gain-of-Function）：野生型 IDH1 催化異檸檬酸轉(zhuǎn)化為 $\alpha$-酮戊二酸（$\alpha$-KG），而突變型的 IDH1 酶獲得了全新的功能（Gain-of-function），會逆向?qū)?$\alpha$-KG 進一步還原為“癌性代謝物”——D-2-羥基戊二酸（D-2-hydroxyglutarate, D-2HG）。該細胞系在體外培養(yǎng)時能夠持續(xù)穩(wěn)定地高豐度分泌 D-2HG。

  • 伴隨突變（TP53 突變）：該細胞系同時攜帶純合的 TP53 基因 245 位點突變（甘氨酸 Gly 突變?yōu)槔i氨酸 Val），完美模擬了臨床上 IDH 突變型神經(jīng)膠質(zhì)瘤常伴隨 p53 通路失活的真實分子病理圖譜。

• 生長特性：貼壁生長（Adherent growth），主要呈現(xiàn)典型的神經(jīng)膠質(zhì)/星形細胞多角形或紡錘形形態(tài)。

• 生物安全級別：1級或2級潛力（BSL-1 / BSL-2 視各實驗室人類來源樣本規(guī)范而定）。菌株/細胞已通過 Charles River 的人類基本傳染病篩查（CLEAR panel），證實無支原體、無小鼠/大鼠/非人靈長類等外源交叉污染。

二 核心科研價值與轉(zhuǎn)化醫(yī)學應用

傳統(tǒng)上，含有天然 IDH1 突變的原代膠質(zhì)瘤細胞極其難以在體外長期傳代，突變位點極易在人工培養(yǎng)中丟失。TB096 是目前國際公認的、極少數(shù)能長久穩(wěn)定維持 IDH1 R132H 突變表型的標準化體外細胞模型：

1. 致癌腫瘤代謝學（Oncometabolism）研究：用于深入探究 D-2HG 在胞內(nèi)積累后如何引發(fā)全面性的 DNA 惡性超甲基化（Hypermethylation）以及組蛋白修飾改變，進而阻斷星形膠質(zhì)細胞的正常分化并驅(qū)動癌變的精細機制。

2. 靶向藥物研發(fā)與耐藥性監(jiān)控（Drug Screening）：是篩選新型突變型 IDH1 小分子抑制劑（如 Vorasidenib、Ivosidenib）以及評估靶向藥物在克服血腦屏障（BBB）后體外殺傷動力學的首選陽性細胞模型，常用于研究 PHGDH 或其他代謝通路引發(fā)的獲得性耐藥。

3. 同源異形控制模型（Isogenic Tumor Modeling）：可利用 CRISPR/Cas9 或 AAV 基因靶向技術(shù)敲除其突變或野生型等位基因，構(gòu)建完美的同源細胞控制矩陣。

三 實驗室細胞復蘇、擴增傳代與冷凍保存標準步驟

1. 專用培養(yǎng)基配置（Expansion Medium）

TB096 屬于神經(jīng)外胚層來源的高級惡性腫瘤細胞，對血清質(zhì)量和基質(zhì)滲透壓有特定要求：

• 基礎(chǔ)配置方案（混合培養(yǎng)基，推薦）：

  • 50% NBE 培養(yǎng)基 + 50% DMEM 高糖培養(yǎng)基

  • 補充添加：10% 優(yōu)質(zhì)胎牛血清（FBS） + 1% 滅菌雙抗（Penicillin-Streptomycin）。

• 注：若用于維持其干細胞/神經(jīng)球樣分化潛能，部分實驗室會使用不含血清的神經(jīng)干細胞增殖培養(yǎng)基（補充 20 ng/mL EGF 和 10 ng/mL bFGF），但貼壁常規(guī)擴增首選上述含血清配方。

2. 細胞復蘇（Thawing Protocol）

1. 從液氮罐中取出 TB096 凍存管，立即投入 37 攝氏度恒溫水浴箱中，輕微晃動。

2. 在 1 到 2 分鐘內(nèi)令其急速完全融化（至僅剩極小冰芯）。注：復蘇過程必須極為迅速，避免二甲基亞砜（DMSO）在室溫融化狀態(tài)下對細胞產(chǎn)生強烈的細胞毒性。

3. 消毒凍存管外部，移入生物安全柜。用移液管將細胞懸液吸出，置于 15 mL 干凈離心管中。

4. 極重要（防止?jié)B透壓休克）：用移液管吸取 9 mL 預熱的 TB096 專用擴增培養(yǎng)基，以滴加的方式（Dropwise）極其緩慢地加入到離心管中，期間輕輕轉(zhuǎn)動離心管。嚴禁一次性快速傾倒全部培養(yǎng)基！

5. 300 × g 離心 2 至 3 分鐘，輕輕倒掉含有 DMSO 的上清液。

6. 加入 2-5 mL 新鮮培養(yǎng)基，用移液槍極輕柔地吹打 2 次以重懸細胞，嚴禁劇烈震蕩（Vortex）。隨后接種于培養(yǎng)瓶中，置于 37°C、5% $CO_2$ 孵箱中培養(yǎng)。

3. 細胞傳代（Passaging / Subculture）

• 傳代時機：切勿讓細胞長至 100% 完全融合。當細胞密度達到約 70% - 80% 融合度時必須執(zhí)行傳代。

• 傳代步驟：

  1. 吸除舊培養(yǎng)基，使用無菌 PBS 輕輕洗滌細胞表面 1-2 次。

  2. 加入適量 Accutase?（阿庫酶/廣譜細胞消化液）（一般 T25 瓶加 2-3 mL，T75 瓶加 5-7 mL），確保覆蓋細胞。

  3. 置于 37°C 孵箱中消化 3 至 5 分鐘。在顯微鏡下觀察，當絕大部分細胞變圓且開始脫離瓶壁時，輕輕拍打瓶身使其完全脫落。

  4. 加入 2 倍體積的常規(guī)擴增培養(yǎng)基終止消化，收集至離心管中。

  5. 計數(shù)后，按照常規(guī) 1:4 至 1:6 的比例（根據(jù)細胞活力及實驗周期調(diào)整）傳代接種到新的培養(yǎng)皿/瓶中。

4. 細胞冷凍保存（Cryopreservation）

• 凍存液配方：90% 優(yōu)質(zhì)胎牛血清（FBS）+ 10% 醫(yī)用級 DMSO，或使用無血清無蛋白的高效細胞凍存液。

• 凍存操作：收集處于對數(shù)生長旺盛期（融合度約 75%）的細胞，離心棄上清。調(diào)整細胞密度至 $\ge 1 \times 10^6$ cells/vial。加入凍存液重懸后分裝入凍存管，立即投入標準程序降溫盒（異丙醇梯度降溫盒，1°C/min），置于 -80°C 過夜，次日必須轉(zhuǎn)移至 -196°C 液氮中進行無限期冷凍長期保存。

PART 2 ENGLISH SECTION

I General Information and Genetic Architecture

• Cell Line Name: TB096 (Also specified as TB096-2 or TB096-0096) Human IDH1-Mutated Astrocytoma Cell Line.

• Species Origin: Human.Derived from a 26-year-old male patient diagnosed with anaplastic astrocytoma (WHO Grade III) treated at Duke University in 2009.Tissues were harvested under full Institutional Review Board (IRB) compliance and patient written consent.

• Core Genetic and Molecular Signatures:

  • Heterozygous IDH1 R132H Mutation: Represents an invaluable, globally recognized stable in vitro platform harboring the definitive Arg132 to Histidine (R132H) single point mutation within the IDH1 (NADP+-dependent isocitrate dehydrogenase 1) locus.

  • Oncometabolite D-2HG Hyper-Secretion (Gain-of-Function): While wild-type IDH1 converts isocitrate to $\alpha$-ketoglutarate ($\alpha$-KG), the mutated IDH1 enzyme acquires an aggressive oncogenic gain-of-function metabolic profile.It sequentially reduces $\alpha$-KG into the prominent oncometabolite D-2-hydroxyglutarate (D-2HG). This cell line consistently manufactures and releases high baseline titers of D-2HG into culture supernatants.

  • Concomitant TP53 Disruption: Co-harbors a homozygous TP53 mutation at codon 245 (Gly to Val substitution), perfectly mirroring the actual clinical, co-occurring molecular pathology found in human IDH-mutant astrocytic lineages.

• Growth Topology: Adherent growth mode. Displays distinct polygonal, bipolar, or spindle-shaped astrocytic/glial morphologies.

• Biosafety Matrix: BSL-1 or BSL-2 depending on institutional biosafety guidelines for handling human-derived materials. Verified strictly negative for mycoplasma, viral pathogens, and interspecies cross-contaminations (tested negative via the Charles River Human Essential CLEAR panel).

II Strategic Research Value & Translational Fields

Primary glioma cells isolating endogenous IDH1 mutations historically suffer from an inability to propagate long-term in vitro, rapidly losing or counter-selecting the mutant allele across passages. TB096 stands out as a robust model that preserves the intact IDH1 R132H mutational phenotype across decades of subculturing:

1. Cancer Oncometabolism Exploration: Ideal for decoding downstream epigenetic reprogramming, specifically how chronic intracellular D-2HG pooling drives systemic CpG island methylator phenotypes (G-CIMP), inhibits $\alpha$-KG-dependent dioxygenases, blocks differentiation, and dictates gliomagenesis.

2. Targeted Therapeutics & Resistance Screens: Serves as a definitive positive control model for validating small-molecule mutant-IDH1 dual-inhibitors (e.g., Vorasidenib, Ivosidenib), mapping pharmacological parameters across the blood-brain barrier (BBB), and identifying alternate enzymatic escape loops (such as PHGDH-driven bypass resistance).

3. Isogenic Modification & Metrology: Provides a uniform target for CRISPR-Cas9 or AAV-mediated homologous editing to engineer clean wild-type/mutant paired control cell matrices.

III Thawing, Proliferation, Passaging, and Cryopreservation Routines

1. Formulating the Complete Expansion Medium

As neuroectodermal malignant cells, TB096 demands exact nutritional osmolarity balances:

• Standard Dual-Base Protocol (Highly Recommended):

  • 50% NBE (Neurobasal Medium Alternate) + 50% High-Glucose DMEM

  • Supplements: Fortified with 10% premium Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin cocktail.

• Note: For highly specialized neurosphere lineage maintenance, some pipelines implement serum-free neural stem frameworks supplemented with 20 ng/mL EGF and 10 ng/mL bFGF; however, regular monolayer proliferation is optimally driven by the serum-fortified matrix above.

2. Cryovial Thawing Routine

1. Retrieve the TB096 cryovial from liquid nitrogen storage and instantly submerge it into a 37°C water bath with gentle agitation.

2. Complete the thawing cycle rapidly within 1 to 2 minutes (stop when a minuscule ice crystal remains). Note: Rapid thawing is mandatory to prevent prolonged ambient exposure to liquefied DMSO, which exercises acute chemical cytotoxicity.

3. Disinfect the vial exterior with 70% ethanol, transit into a biosafety cabinet, and siphon the cells into a sterile 15 mL conical tube.

4. CRITICAL STEP (Osmotic Shock Countermeasure): Utilizing a serological pipette, draw 9 mL of pre-warmed complete Expansion Medium. Slowly add the medium dropwise to the cell pellet while gently swirling the tube. Never dump the entire volume of media all at once into the cells.

5. Centrifuge the suspension at 300 × g for 2 to 3 minutes, then decant the DMSO-polluted supernatant.

6. Replenish with 2–5 mL of fresh medium, and gently pipette up and down twice to resuspend the cells. Do not vortex. Plate the cell slurry into standard culture flasks and incubate at 37°C under 5% $CO_2$.

3. Subculturing and Cell Passaging Guide

• Confluency Threshold: Do not allow the cultures to grow to 100% confluency. Execute passaging promptly when the monolayer strikes 70%–80% confluency.

• Step-by-Step Harvesting:

  1. Aspirate the spent culture medium and gently wash the adherent layers 1–2 times with sterile PBS.

  2. Disperse an optimal volume of Accutase? Dissociation Solution across the matrix (approx. 2–3 mL for T25 flasks; 5–7 mL for T75 flasks).

  3. Incubate at 37°C for 3 to 5 minutes. Monitor under an inverted microscope; as soon as the cells round up and start detaching, gently tap the flask to dislodge the remaining layer.

  4. Quench the enzyme immediately by introducing a double volume of serum-containing complete Expansion Medium, then transfer the slurry into a conical tube.

  5. Perform a cell count via hemocytometer and re-plate into fresh flasks at a standard split ratio of 1:4 to 1:6.

4. Cryopreservation Protocol

• Freezing Medium Matrix: 90% Premium FBS + 10% Tissue-Culture Grade DMSO, or validated protein-free commercial cryopreservation solutions.

• Freezing Routine: Harvest cells harvesting during their active log-growth phase (~75% confluent). Spin down, discard supernatant, and adjust the cell density to $\ge 1 \times 10^6$ viable cells/vial. Aliquot into cryovials and place inside a standardized isopropyl alcohol freezing container (giving a cooling rate of -1°C/minute). Stash at -80°C overnight, and transfer into liquid nitrogen (-196°C) the following day for indefinite preservation.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com